Printer Friendly

Colitis Therapeutic Pipeline Market Analysis of 10 Companies and 24 Drugs H1 2015 Review Research Report.

DALLAS, March 10, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Colitis - Pipeline Review, H1 2015" therapeutic market research report of 74 pages with latest updates, data and information to its online business intelligence library.

The report Colitis Pipeline Review, H1 2015 provides an overview of the Colitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects. Complete report is available @ http://www.rnrmarketresearch.com/colitis-pipeline-review-h1-2015-market-report.html.

Colitis is inflammation of the inner lining of the colon. It may cause abdominal pain and diarrhea with or without blood. Fever may be present. There are numerous causes of colitis including infection, inflammatory bowel disease, ischemic, and microscopic colitis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies discussed in this report include : Ajinomoto Pharmaceuticals Co., Ltd., Akebia Therapeutics, Inc., BioLineRx, Ltd., Cognosci, Inc., Galapagos NV, GeneFrontier Corporation, Inovio Pharmaceuticals, Inc., N30 Pharmaceuticals, Prokarium Ltd., Protalix BioTherapeutics, Inc., Synovo GmbH. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=308841. (This is a premium report priced at US$2000 for a single user License.)

Drugs profile discussed in this report include: AcTMP-1, AKB-6899, APY-0201, BC-1215, BL-5040, C-142, clostridium difficile vaccine, COG-112, CSY-0073, etanercept biosimilar, filgotinib, GFC-101, N-6022, N-6547, NK-007, Peptide to Inhibit NFkB for Colitis and Enteritis, RNAi Oligonucleotides to Inhibit TNFalpha for IBD and Colitis, Small Molecule for Colitis, Synthetic Peptide for Gastrointestinal, Respiratory and CNS Disorders, Synthetic Peptides to Inhibit Panx1 for Colitis, Vaccine for Colitis, Vaccine to Target Interleukin-23 for Colitis, VGX-1027.

Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.

Reasons to buy

* Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

* Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

* Develop strategic initiatives by understanding the focus areas of leading companies

* Identify and understand important and diverse types of therapeutics under development for Colitis

* Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

* Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics

* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports of Gastrointestinal Therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/gastrointestinal-therapeutics.

Other Related Reports:

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2015

The report Reflux Esophagitis (Gastroesophageal Reflux Disease) Pipeline Review, H1 2015 provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Ulcerative Colitis - Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Ulcerative Colitis. Companies discussed in this report include Ajinomoto Pharmaceuticals Co., Ltd., AlphaMab Co., Ltd, Altheus Therapeutics, Inc., Am-Pharma B.V., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Athersys, Inc., Atlantic Healthcare plc, Avaxia Biologics, Inc., Biocon Limited, BioLineRx, Ltd., Bristol-Myers Squibb Company, Celgene Corporation, Cellceutix Corporation, Celltrion, Inc., ChemoCentryx, Inc., ChironWells GmbH, Cosmo Pharmaceuticals S.p.A, Dr. Falk Pharma GmbH, Drais Pharmaceuticals, Inc., Effimune SAS, Emergent BioSolutions Inc., Enceladus Pharmaceuticals BV, Epirus Biopharmaceuticals, Inc., Euroscreen S.A., Farmacija d.o.o. Tuzla, Flexion Therapeutics, Inc., Galapagos NV, Genentech, Inc., Genfit SA, Genor BioPharma Co., Ltd., Gilead Sciences, Inc., GT Biologics Limited, GW Pharmaceuticals plc, iCo Therapeutics Inc., InDex Pharmaceuticals AB, INOXIA Lifesciences GmbH, Invion Limited, Johnson & Johnson

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:

G+ / Google Plus: https://plus.google.com/u/0/104156468549256253075/

Twitter: https://twitter.com/RnRMR

Facebook: http://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

Contact: Ritesh Tiwari TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252 Tel: +1-888-391-5441 E-mail: sales@rnrmarketresearch.com
COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:Mar 10, 2015
Words:1204
Previous Article:The Companion Diagnostics (CDx) Market Forecast 2015-2025.
Next Article:PAY.ON and Planet Payment Announce Strategic Partnership to Power Planet Payment's International Gateway.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters